Search Bar & Filters
Found 2 Actively Recruiting clinical trials
Actively Recruiting
Sickle cell anemia SCA is a severe blood disorder affecting over 300,000 newborns annually, mainly in sub-Saharan Africa where many children die early due to lack of diagnosis and care. This trial evaluates hydroxyurea, a daily oral medication used safely in high-resource settings, now being studied with a new precision dosing approach to improve safety and effectiveness in African children with SCA. The study is a randomized clinical trial aiming to develop evidence-based dosing and monitoring guidelines for hydroxyurea in this region. Participants will receive hydroxyurea either at a standard weight-based dose or an individualized dose guided by pharmacokinetics using a battery-powered machine and automated algorithm. This approach includes limited laboratory monitoring to make treatment more accessible in low-resource settings. The study involves 400 children with SCA in Luanda, Angola, comparing these two dosing strategies. During the trial, children will be monitored for clinical adverse events and laboratory responses over approximately 24 months. Researchers will assess the rate of serious sickle cell complications and other adverse events, alongside blood responses at 12 months. The study involves regular evaluations to ensure safety and gather data on the best dosing and monitoring practices, aiming to support widespread hydroxyurea use across sub-Saharan Africa.
Actively Recruiting
Researchers are studying genetic modifiers in hemoglobinopathies, including sickle cell disease and beta-thalassemia, through a large-scale, multi-ethnic genome-wide association study GWAS. These diseases vary widely in severity, influenced partly by genetic factors. The study aims to discover new genetic modifiers, validate known ones, pool existing genomic data, standardize disease descriptions, create a comprehensive research resource, and develop risk scores to help stratify patients based on disease severity and treatment response. The study will collect blood samples during routine clinical visits to perform GWAS experiments on individuals with hemoglobinopathies. Participants include those with various genotypes of sickle cell disease, beta-thalassemia, and alpha-thalassemia, without restrictions on gender or ethnicity. All participants will provide consent, and DNA samples may be collected if not already available in existing biobanks. Participants will contribute data including genetic, phenotypic, and functional information. The study will analyze worldwide patient demographics, genotypes, and disease severity. Researchers will investigate genetic modifiers related to survival, neurological function, renal impairment, pain syndromes, pulmonary hypertension, and treatment responses. This observational study involves data collection over five years, with no investigational treatments administered.